<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1011404</article-id><article-id pub-id-type="publisher-id">ACM-38754</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201100000_25712605.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  沙库巴曲缬沙坦对非ST段抬高型心肌梗死伴心功能不全且行PCI术患者的疗效分析
  Analysis of the Efficacy of Sakubatrovalsartan in Non-ST-Segment Elevation Myocardial Infarction Patients with Cardiac Insufficiency Undergoing PCI
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>崔</surname><given-names>述霞</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>黄</surname><given-names>玉晓</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>荣</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>马</surname><given-names>侃侃</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>松</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院，山东 青岛</addr-line></aff><aff id="aff3"><addr-line>青岛市中医医院，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>11</month><year>2020</year></pub-date><volume>10</volume><issue>11</issue><fpage>2654</fpage><lpage>2659</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：本文旨在探究沙库巴曲缬沙坦(ARNI)在治疗非ST段抬高型心肌梗死(NSTEMI)伴心功能不全且行经皮冠状动脉介入治疗(PCI)术患者近期治疗的效果。方法：随机选取2018.06.01~2019.12.30青岛大学附属医院78例非ST段抬高型心肌梗死伴心功能不全且行PCI术患者，应用随机数字表法将其随机分为两组，其中观察组40例，在常规基础上应用沙库巴曲缬沙坦治疗，对照组38例，在常规基础上应用缬沙坦治疗。监测观察组及对照组血清N-末端B型利钠肽前体(NT-proBNP)以及左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)等心脏指标的变化，术后6月的临床疗效，发生药物不良反应例数以及再次住院例数。结果：a) 两组患者术后6月血NT-proBNP水平较出院前均明显下降，差异有统计学意义(P &lt; 0.01)；且术后6月观察组血清NT-proBNP水平低于对照组(P &lt; 0.01)。b) 两组患者术后6月LVEF、LVEDD等心脏超声指标较术前均有所改善，差异有统计学意义(P &lt; 0.01)，观察组改善情况优于对照组(P &lt; 0.01)。c) 出院治疗6个月后，观察组临床疗效优于对照组(P &lt; 0.01)。结论：沙库巴曲缬沙坦应用于非ST段抬高型心肌梗死伴心功能不全且行PCI术患者中的疗效优于缬沙坦，并且可以有效逆转心室重构，改善患者的临床预后。
    Objective: In this study, we aimed to investigate the short-term efficacy of sakubatrovalsartan (ARNI) in patients, who were diagnosed for non-ST-segment elevation myocardial infarction (NSTEMI) com- plicated by cardiac insufficiency, subsequently underwent percutaneous coronary intervention (PCI). Method: A total of 78 NSTEMI patients complicated by cardiac insufficiency receiving PCI were selected in the Affiliated Hospital of Qingdao University from June 2018 to December 2019. Then they were randomly divided into the observation group (n = 40) and the control group (n = 38). In addition to conventional treatment, sakubatrovalsartan was used in the observation group, and valsartan was given in the control group. Drug efficacy and cardiac indicators including N-terminal B-type natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), left ventricular end-diastolic inner diameter (LVEDD) before operation and 6 months after operation, cases with adverse events, cases of re-hospitalization were compared between the two groups. Results: a) There were statistically significant differences in blood NT-proBNP levels before discharge and 6 months after surgery in two groups, respectively (p &lt; 0.01). NT-proBNP in the observation group was lower than that in the control group (p &lt; 0.01). b) Cardiac ultrasound indicators such as LVEF, LVEDD before and 6 months after surgery showed statistical improvements between the two groups (P &gt; 0.05), respectively. The improvement of observation group was better than that of control group (p &lt; 0.01). c) After 6 months of treatment, the clinical effect of observation group was better than that of control group (P &lt; 0.01). Conclusion: The sakubatrovalsartan, was superior to valsartan for NSTEMI patients receiving PCI with concomitant cardiac insufficiency, which can effectively reverse ventricular remodeling and improve the clinical prognosis of patients. 
  
 
</p></abstract><kwd-group><kwd>沙库巴曲缬沙坦，非ST段抬高型心肌梗死，心功能不全, Sakubatrovalsartan</kwd><kwd> Non-ST-Segment Elevation Myocardial Infarction</kwd><kwd> Cardiac Insufficiency</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：本文旨在探究沙库巴曲缬沙坦(ARNI)在治疗非ST段抬高型心肌梗死(NSTEMI)伴心功能不全且行经皮冠状动脉介入治疗(PCI)术患者近期治疗的效果。方法：随机选取2018.06.01~2019.12.30青岛大学附属医院78例非ST段抬高型心肌梗死伴心功能不全且行PCI术患者，应用随机数字表法将其随机分为两组，其中观察组40例，在常规基础上应用沙库巴曲缬沙坦治疗，对照组38例，在常规基础上应用缬沙坦治疗。监测观察组及对照组血清N-末端B型利钠肽前体(NT-proBNP)以及左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)等心脏指标的变化，术后6月的临床疗效，发生药物不良反应例数以及再次住院例数。结果：a) 两组患者术后6月血NT-proBNP水平较出院前均明显下降，差异有统计学意义(P &lt; 0.01)；且术后6月观察组血清NT-proBNP水平低于对照组(P &lt; 0.01)。b) 两组患者术后6月LVEF、LVEDD等心脏超声指标较术前均有所改善，差异有统计学意义(P &lt; 0.01)，观察组改善情况优于对照组(P &lt; 0.01)。c) 出院治疗6个月后，观察组临床疗效优于对照组(P &lt; 0.01)。结论：沙库巴曲缬沙坦应用于非ST段抬高型心肌梗死伴心功能不全且行PCI术患者中的疗效优于缬沙坦，并且可以有效逆转心室重构，改善患者的临床预后。</p></sec><sec id="s2"><title>关键词</title><p>沙库巴曲缬沙坦，非ST段抬高型心肌梗死，心功能不全</p></sec><sec id="s3"><title>Analysis of the Efficacy of Sakubatrovalsartan in Non-ST-Segment Elevation Myocardial Infarction Patients with Cardiac Insufficiency Undergoing PCI<sup> </sup></title><p>Shuxia Cui<sup>1</sup>, Yuxiao Huang<sup>2</sup>, Rong Li<sup>1</sup>, Kankan Ma<sup>1</sup>, Song Liu<sup>1</sup></p><p><sup>1</sup>The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Qingdao Hospital of Traditional Chinese Medicine, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/38-1571696x4_hanspub.png" /></p><p>Received: Nov. 2<sup>nd</sup>, 2020; accepted: Nov. 18<sup>th</sup>, 2020; published: Nov. 25<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/38-1571696x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: In this study, we aimed to investigate the short-term efficacy of sakubatrovalsartan (ARNI) in patients, who were diagnosed for non-ST-segment elevation myocardial infarction (NSTEMI) com- plicated by cardiac insufficiency, subsequently underwent percutaneous coronary intervention (PCI). Method: A total of 78 NSTEMI patients complicated by cardiac insufficiency receiving PCI were selected in the Affiliated Hospital of Qingdao University from June 2018 to December 2019. Then they were randomly divided into the observation group (n = 40) and the control group (n = 38). In addition to conventional treatment, sakubatrovalsartan was used in the observation group, and valsartan was given in the control group. Drug efficacy and cardiac indicators including N-terminal B-type natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), left ventricular end-diastolic inner diameter (LVEDD) before operation and 6 months after operation, cases with adverse events, cases of re-hospitalization were compared between the two groups. Results: a) There were statistically significant differences in blood NT-proBNP levels before discharge and 6 months after surgery in two groups, respectively (p &lt; 0.01). NT-proBNP in the observation group was lower than that in the control group (p &lt; 0.01). b) Cardiac ultrasound indicators such as LVEF, LVEDD before and 6 months after surgery showed statistical improvements between the two groups (P &gt; 0.05), respectively. The improvement of observation group was better than that of control group (p &lt; 0.01). c) After 6 months of treatment, the clinical effect of observation group was better than that of control group (P &lt; 0.01). Conclusion: The sakubatrovalsartan, was superior to valsartan for NSTEMI patients receiving PCI with concomitant cardiac insufficiency, which can effectively reverse ventricular remodeling and improve the clinical prognosis of patients.</p><p>Keywords:Sakubatrovalsartan, Non-ST-Segment Elevation Myocardial Infarction, Cardiac Insufficiency</p><disp-formula id="hanspub.38754-formula27"><graphic xlink:href="//html.hanspub.org/file/38-1571696x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/38-1571696x7_hanspub.png" /> <img src="//html.hanspub.org/file/38-1571696x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>非ST段抬高型心肌梗死为急性冠脉综合征的一种类型，其临床表现与ST段抬高型心肌梗死相似，主要表现为持续不缓解的胸痛，心电图呈现心肌缺血的表现，但不伴随ST段抬高；其发生率及死亡率均较高，PCI为其主要治疗手段，可明显缓解临床症状，降低再发率及死亡率 [<xref ref-type="bibr" rid="hanspub.38754-ref1">1</xref>]。心肌梗死后常伴随心肌组织不同程度的损伤，容易导致心力衰竭的发生。目前心力衰竭的治疗仍是一大难题，除传统的金三角治疗药物外，沙库巴曲缬沙坦为全球首个血管紧张素脑啡肽酶抑制剂，具有增加脑啡肽酶活性，同时抑制血管紧张素的双重作用 [<xref ref-type="bibr" rid="hanspub.38754-ref2">2</xref>]，在2016年欧洲急慢性心力衰竭指南中获得了Ⅰ类推荐 [<xref ref-type="bibr" rid="hanspub.38754-ref3">3</xref>]，治疗慢性心力衰竭效果显著，其在心肌梗死合并心力衰竭中的研究较少。本文旨在探讨沙库巴曲缬沙坦在非ST段抬高型心肌梗死伴心功能不全且行PCI术患者中的治疗效果。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 研究对象的确定及基本资料</title><p>随机选取2018.06.01~2019.12.30青岛大学附属医院78例非ST段抬高型心肌梗死伴心功能不全患者，入院后行PCI术，随机分为观察组(n = 40)和对照组(n = 38)。其中观察组男23例，女17例，对照组男20例，女18例。本次研究已获得医院医学伦理委员会的批准。</p><p>入选及排除标准：入选标准：1) 符合非ST段抬高型心肌梗死的诊断标准；2) 合并心功能不全，心功能NYHA分级为II~IV级；3) 入院后行PCI术治疗；4) 获得患者及家属的知情同意。排除标准：1) ST段抬高型心肌梗死；2) 继发于甲亢，心肌炎，肺动脉高压等疾病的心功能不全患者；3) 存在严重肝肾功能不全患者；4) 存在自身免疫性、传染性、出血性疾病、严重创伤或者肿瘤患者；5) 对造影剂过敏或不耐受沙库巴曲缬沙坦的患者。</p></sec><sec id="s6_2"><title>2.2. 研究方法</title><p>观察组及对照组术后均常规药物治疗，包括积极双联抗血小板，抗凝，调节血脂，扩张冠状动脉，营养心肌等对症支持治疗。观察组在常规治疗(不包括ACEI/ARB类)的基础上应用沙库巴曲缬沙坦(若之前应用ACEI类药物治疗心脏疾病需停药36小时后应用ARIN)，初始剂量为每日2次，每次50 mg，随后根据患者耐受情况及治疗效果，倍增剂量，直至达到最大耐受剂量(每日2次，每次100~200 mg，理想靶剂量为200 mg)。对照组在常规基础上服用缬沙坦(每日1次，每次80 mg)。</p></sec><sec id="s6_3"><title>2.3. 观察指标</title><p>1) 心功能指标：观察两组患者出院前及治疗6月后血清NT-proBNP变化。使用Philips EPIQ 7C彩色多普勒超声诊断仪，配备S5-1探头(探头频率1.0~5.0 MHz)测量LVEF、LVEDD等反应左室功能的心脏指标，观察两组术前及术后6月指标的变化。</p><p>2) 预后指标：观察两组术前及术后6月后的临床疗效(以6 min步行试验的结果初步判断)，根据2002年由美国胸科协会发表的6 min步行试验指南 [<xref ref-type="bibr" rid="hanspub.38754-ref4">4</xref>] 提示，6 min步行试验(6 minutes walk test, 6MWT))是一种简单易行，耐受性较好，结果比较客观反映日常活动的试验，可作为评价心力衰竭患者治疗效果及预后的重要工具，根据6MWT操作标准进行判断，显效：步行距离大于450 m，NYHAⅠ级；有效：步行距离为150~450 m之间，NYHAⅡ级；无效：步行距离小于150 m，NYHAⅢ-Ⅳ级；同时定义总有效数为显效与有效之和。</p><p>3) 不良反应发生情况，记录包括低血压，高血钾，肾功能不全，干咳、血管神经性水肿等在内的不良反应发生例数，以及再次住院例数。</p></sec><sec id="s6_4"><title>2.4. 统计学方法</title><p>应用SPSS 23.0统计软件对数据进行统计学分析。计量资料用卡方检验，根据最小理论数值选择Pearson卡方或者连续性校正的卡方；计数资料结果用均数 &#177; 标准差( x &#175; &#177; s )表示，两组间比较采用独立样本t检验，组内比较采用配对t检验。</p></sec></sec><sec id="s7"><title>3. 研究结果</title><sec id="s7_1"><title>3.1. 基线资料比较</title><p>观察组共40例患者，包括男23例，女17例，平均年龄(62.32 &#177; 8.73)岁，其中高血压31例，糖尿病29例；对照组共38例病号，其中男20例，女18例，平均年龄(65.10 &#177; 9.40)岁，高血压28例，糖尿病26例；经统计学分析，两组基本资料差异无统计学意义(P &gt; 0.05)；见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of clinical traits between the two groups ( x &#175; &#177; S </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >指标</th><th align="center" valign="middle" >观察组</th><th align="center" valign="middle" >对照组</th><th align="center" valign="middle" >c<sup>2</sup>/t值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >性别(男，n)</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >0.187</td><td align="center" valign="middle" >0.820</td></tr><tr><td align="center" valign="middle" >年龄(岁， x &#175; &#177; S )</td><td align="center" valign="middle" >62.32 &#177; 8.73</td><td align="center" valign="middle" >65.10 &#177; 9.40</td><td align="center" valign="middle" >1.353</td><td align="center" valign="middle" >0.180</td></tr><tr><td align="center" valign="middle" >高血压(n)</td><td align="center" valign="middle" >31</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >0.154</td><td align="center" valign="middle" >0.784</td></tr><tr><td align="center" valign="middle" >糖尿病(n)</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >0.156</td><td align="center" valign="middle" >0.805</td></tr></tbody></table></table-wrap><p>表1. 两组临床基线资料比较( x &#175; &#177; S )</p></sec><sec id="s7_2"><title>3.2. 血清NT-proBNP变化</title><p>出院前两组无统计学差异(P &gt; 0.05)，出院前与术后6月相比较，观察组与对照组两组组内均存在统计学差异(P &lt; 0.01)，术后6月两组间存在统计学差异(P &lt; 0.01)；见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Concentration of NT-proBNP before and after treatment in the two groups respectively ( x &#175; &#177; S </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >出院前</th><th align="center" valign="middle" >术后6月</th><th align="center" valign="middle" >t值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >观察组(pg/ml)</td><td align="center" valign="middle" >1425.77 &#177; 1321.28</td><td align="center" valign="middle" >398.98 &#177; 215.75</td><td align="center" valign="middle" >5.468</td><td align="center" valign="middle" >&lt;0.01</td></tr><tr><td align="center" valign="middle" >对照组(pg/ml)</td><td align="center" valign="middle" >1576.21 &#177; 1107.40</td><td align="center" valign="middle" >789.31 &#177; 357.74</td><td align="center" valign="middle" >5.549</td><td align="center" valign="middle" >&lt;0.01</td></tr><tr><td align="center" valign="middle" >t值</td><td align="center" valign="middle" >0.544</td><td align="center" valign="middle" >5.869</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >0.588</td><td align="center" valign="middle" >&lt;0.01</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表2. 两组治疗前后NT-proBNP变化( x &#175; &#177; S )</p></sec><sec id="s7_3"><title>3.3. 心脏指标变化</title><p>LVEF、LVEDD术前两组间无统计学差异(P &gt; 0.05)，术前与术后6月相比较，观察组与对照组两组组内均存在统计学差异(P &lt; 0.01)，术后6月两组间存在统计学差异(P &lt; 0.05)；见表3，表4。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of LVEF between the two groups ( x &#175; &#177; S </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >术前</th><th align="center" valign="middle" >术后6月</th><th align="center" valign="middle" >t值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >观察组(%)</td><td align="center" valign="middle" >38.12 &#177; 11.86</td><td align="center" valign="middle" >47.25 &#177; 10.70</td><td align="center" valign="middle" >14.862</td><td align="center" valign="middle" >&lt;0.01</td></tr><tr><td align="center" valign="middle" >对照组(%)</td><td align="center" valign="middle" >35.89 &#177; 10.26</td><td align="center" valign="middle" >41.36 &#177; 9.66</td><td align="center" valign="middle" >11.981</td><td align="center" valign="middle" >&lt;0.01</td></tr><tr><td align="center" valign="middle" >t值</td><td align="center" valign="middle" >1.283</td><td align="center" valign="middle" >2.554</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >0.203</td><td align="center" valign="middle" >0.013</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表3. 两组治疗前后LVEF变化( x &#175; &#177; S )</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Comparison of LVEDD between the two groups ( x &#175; &#177; S </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >术前</th><th align="center" valign="middle" >术后6月</th><th align="center" valign="middle" >t值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >观察组(cm)</td><td align="center" valign="middle" >5.72 &#177; 0.67</td><td align="center" valign="middle" >4.77 &#177; 0.51</td><td align="center" valign="middle" >13.942</td><td align="center" valign="middle" >&lt;0.01</td></tr><tr><td align="center" valign="middle" >对照组(cm)</td><td align="center" valign="middle" >5.80 &#177; 0.62</td><td align="center" valign="middle" >5.25 &#177; 0.52</td><td align="center" valign="middle" >11.483</td><td align="center" valign="middle" >&lt;0.01</td></tr><tr><td align="center" valign="middle" >t值</td><td align="center" valign="middle" >0.529</td><td align="center" valign="middle" >4.160</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >0.598</td><td align="center" valign="middle" >&lt;0.01</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表4. 两组治疗前后LVEDD变化( x &#175; &#177; S )</p></sec><sec id="s7_4"><title>3.4. 临床疗效</title><p>术后6月观察组临床症状较对照组改善明显，两组疗效存在统计学差异(P &lt; 0.05)；见表5。</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Comparison of efficacy between the two groups ( x &#175; &#177; S </title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >组别</th><th align="center" valign="middle"  colspan="2"  >总有效</th><th align="center" valign="middle"  rowspan="2"  >无效</th><th align="center" valign="middle"  rowspan="2"  >c<sup>2</sup>值</th><th align="center" valign="middle"  rowspan="2"  >P值</th></tr></thead><tr><td align="center" valign="middle" >显效</td><td align="center" valign="middle" >有效</td></tr><tr><td align="center" valign="middle" >观察组(n)</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >2</td><td align="center" valign="middle"  rowspan="2"  >5.616</td><td align="center" valign="middle"  rowspan="2"  >0.023</td></tr><tr><td align="center" valign="middle" >对照组(n)</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >9</td></tr></tbody></table></table-wrap><p>表5. 两组治疗前后临床疗效( x &#175; &#177; S )</p></sec><sec id="s7_5"><title>3.5. 不良反应</title><p>两组均未发生死亡病例，均未出现室性心律失常等严重并发症；其中观察组出现2例(5%)低血压，1例(2.5%)患者因临床症状加重再次入院；对照组出现1例(2.6%)低血压，3例(7.9%)患者因症状加重再次入院。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>心力衰竭是目前心脏疾病中的一大难题，心肌梗死后，由于坏死心肌细胞的存在，导致血运重建发生障碍，更容易导致心力衰竭的发生。目前非ST段抬高型心肌梗死所占比例日益增加，合并心力衰竭的群体也逐渐庞大，包括ACEI/ARB、β受体阻断剂、利尿剂在内的被称作金三角的治疗心力衰竭的基石药物均证实无法有效改善心衰长远预后 [<xref ref-type="bibr" rid="hanspub.38754-ref5">5</xref>]。</p><p>沙库巴曲缬沙坦是一种复合制剂，通过NO-cGMP-PKG细胞信号传导通路以及抑制RAAS系统(Renin-Angiotensin-Aldosterone System)产生扩张血管、排钠、利尿、抑制心肌细胞纤维化等作用，进而逆转心室重构 [<xref ref-type="bibr" rid="hanspub.38754-ref6">6</xref>]。PARADIGM-HF [<xref ref-type="bibr" rid="hanspub.38754-ref7">7</xref>] 等研究结果统统表明ARNI可有效降低慢性心力衰竭患者的住院率及病死率，进一步证实其在慢性心力衰竭治疗中的有效性及安全性。</p><p>本文旨在探究ARNI在NSTEMI合并心功能不全且行PCI术患者的治疗效果，结果显示观察组6月后临床疗效优于对照组；NT-proBNP水平较出院前明显下降，且下降程度较对照组明显；LVEF较术前明显升高，LVEDD较术前明显缩小，变化均比对照组明显，而且不良反应及再次住院发生例数低于对照组；表明ARNI具有良好的稳定性，相较于缬沙坦可改逆转心室重构，改善临床预后。本研究为单中心临床试验，存在样本量相对较少，研究周期较短等不足，更深刻的机制及潜在不良反应还需进行大规模研究证实。</p><p>综上所述，沙库巴曲缬沙坦治疗非ST段抬高型心肌梗死伴心功能不全且行PCI术患者的临床疗效及预后明显优于缬沙坦。</p></sec><sec id="s9"><title>文章引用</title><p>崔述霞,黄玉晓,李 荣,马侃侃,刘 松. 沙库巴曲缬沙坦对非ST段抬高型心肌梗死伴心功能不全且行PCI术患者的疗效分析Analysis of the Efficacy of Sakubatrovalsartan in Non-ST-Segment Elevation Myocardial Infarction Patients with Cardiac Insufficiency Undergoing PCI[J]. 临床医学进展, 2020, 10(11): 2654-2659. https://doi.org/10.12677/ACM.2020.1011404</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.38754-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Thiele, H., et al. (2018) One-Year Outcomes after PCI Strategies in Cardiogenic Shock. New England Journal of Medicine, 379, 1699-1710. &lt;br&gt;https://doi.org/10.1056/NEJMoa1808788</mixed-citation></ref><ref id="hanspub.38754-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Gu, J., et al. (2010) Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi). Journal of Clinical Pharmacology, 50, 401-414.  
&lt;br&gt;https://doi.org/10.1177/0091270009343932</mixed-citation></ref><ref id="hanspub.38754-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">曾学寨, 刘德平. 2016年欧洲心脏病协会心力衰竭指南解读[J]. 中国心血管杂志, 2016, 21(5): 355-358.</mixed-citation></ref><ref id="hanspub.38754-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">ATS Statement (2002) Guidelines for the Six-Minute Walk Test. American Journal of Respiratory and Critical Care Medicine, 166, 111-117. &lt;br&gt;https://doi.org/10.1164/ajrccm.166.1.at1102</mixed-citation></ref><ref id="hanspub.38754-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Roger, V.L., et al. (2004) Trends in Heart Failure Incidence and Survival in a Community-Based Population. JAMA, 292, 344-350. &lt;br&gt;https://doi.org/10.1001/jama.292.3.344</mixed-citation></ref><ref id="hanspub.38754-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Mangiafico, S., et al. (2013) Neutral Endopeptidase Inhibition and the Natriuretic Peptide System: An Evolving Strategy in Cardiovascular Therapeutics. European Heart Journal, 34, 886-893. &lt;br&gt;https://doi.org/10.1093/eurheartj/ehs262</mixed-citation></ref><ref id="hanspub.38754-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Jessup, M., et al. (2014) PARADIGM-HF—The Experts’ Discussion. New England Journal of Medicine, 371, e15.  
&lt;br&gt;https://doi.org/10.1056/NEJMp1410203</mixed-citation></ref></ref-list></back></article>